{"id":"hycamtin-oral-capsules","safety":{"commonSideEffects":[{"rate":"80","effect":"Neutropenia"},{"rate":"70","effect":"Anemia"},{"rate":"65","effect":"Thrombocytopenia"},{"rate":"60","effect":"Nausea"},{"rate":"40","effect":"Vomiting"},{"rate":"35","effect":"Diarrhea"},{"rate":"50","effect":"Fatigue"},{"rate":"15","effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Topotecan binds to and stabilizes the topoisomerase I-DNA complex, preventing the enzyme from completing its catalytic cycle and leading to accumulation of DNA breaks. This mechanism is particularly effective against cancer cells with high replication rates. The oral capsule formulation allows for convenient at-home administration compared to intravenous alternatives.","oneSentence":"Topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:21.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer (SCLC), relapsed or refractory"},{"name":"Ovarian cancer, relapsed"},{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT06449209","phase":"PHASE2","title":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-05","conditions":"Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer","enrollment":110},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT02030964","phase":"PHASE1","title":"N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2014-01-16","conditions":"Neuroblastoma","enrollment":30},{"nctId":"NCT02308527","phase":"PHASE2","title":"Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2013-07","conditions":"Neuroblastoma","enrollment":225},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":"Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma","enrollment":46},{"nctId":"NCT05736952","phase":"PHASE2","title":"Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-03-01","conditions":"Platinum-resistant Ovarian Cancer","enrollment":""},{"nctId":"NCT02357810","phase":"PHASE2","title":"Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-03-21","conditions":"Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma","enrollment":178},{"nctId":"NCT03987685","phase":"PHASE1","title":"Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Athenex, Inc.","startDate":"2018-07-19","conditions":"Solid Tumor","enrollment":10},{"nctId":"NCT04073550","phase":"PHASE3","title":"Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-10-31","conditions":"Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT00158886","phase":"PHASE1","title":"Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2001-11-08","conditions":"Carcinoma, Renal Cell","enrollment":26},{"nctId":"NCT00800345","phase":"PHASE1","title":"Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors","status":"COMPLETED","sponsor":"Vector Oncology","startDate":"2009-04","conditions":"Gynecologic Tumors","enrollment":33},{"nctId":"NCT00918320","phase":"PHASE2","title":"Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-06","conditions":"Neuroblastoma, Brain Tumors, Solid Tumors","enrollment":129},{"nctId":"NCT00390806","phase":"PHASE3","title":"Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Lung Cancer, Non-Small Cell","enrollment":472},{"nctId":"NCT00698516","phase":"PHASE2","title":"Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HYCAMTIN","oral capsules"],"phase":"phase_3","status":"active","brandName":"HYCAMTIN, oral capsules","genericName":"HYCAMTIN, oral capsules","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cell death in rapidly dividing cancer cells. Used for Small cell lung cancer (SCLC), relapsed or refractory, Ovarian cancer, relapsed, Cervical cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}